Dr. Neil Singla, Chief Scientific Officer of Lotus Clinical Research will chair the 3rd annual American Pain Society Conference on Analgesic Trials on Sunday, March 4, 2018 at the Disneyland Hotel in Anaheim, CA.
PASADENA, CA – November 30, 2017
Lotus Clinical Research is pleased to announce that Dr. Neil Singla will be chairing the 3rd annual American Pain Society Conference on Analgesic Trials. To date there have been hundreds of pain researchers in attendance at APS-CAT discussing the design and conduct of analgesic clinical trials with the expert panels. Audience feedback has been overwhelmingly positive both previous years.
APS’ third annual APS-CAT will be held on Sunday March 4, 2018 (day 1 of APS’ Annual Scientific Summit) at the Disneyland Hotel in Anaheim, CA.
Register Now (you can register for the full APS Summit or select “Pre-Con Only”). Registration is $150, and includes lunch and refreshments. The event is a full day from approximately 8AM-4:30PM.
APS-CAT 2018 confirmed presenters include:
Robert Dworkin, MD
Overcoming False Positive and Negative Results in Chronic Pain Clinical Trials: We’re Going to Need a Bigger (or Better) Boat
Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION)
Neil Singla, MD
Mitigation of Placebo Response through Subject and Investigator Training
Chief Scientific Officer, Lotus Clinical Research
Robert Rappaport, MD
Getting the Indication You Want: Selecting an Appropriate Analgesic Model
Founder, Analgesic Concepts
Former Director, FDA Division of Anesthesia, Analgesia, and Addiction Products
Nathaniel Katz, MD
Using Central Statistical Surveillance to Monitor and Correct Problems that Impact Assay Sensitivity: Recent Findings
CEO, Analgesic Solutions
John Farrar, MD, PhD
Determining if a Chronic Pain Subject Should Be Randomized: Variability in Baseline Pain Diary Data and Other Factors that Affect Assay Sensitivity
Associate Professor, University of Pennsylvania
Co-Director, Biostatistics Analysis Center, Biostatistical and Epidemiology Consulting Center, Center for Clinical Epidemiology and Biostatistics
Roy Freeman, MD
Small Fiber Neuropathy: Implications for Clinical Trials and Drug Development
Professor of Neurology, Harvard Medical School
Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
Ralf Baron, MD
Phenotyping of Neuropathic Pain Patients: Implications for Clinical Trial Design and Drug Development
Head, Division of Neurological Pain Research and Therapy; Vice Chair, Department of Neurology, Christian-Albrechts-Universitaet
APS-CAT is a full-day conference focused on optimizing the design and conduct of analgesic clinical trials. APS-CAT involves audience members in dialogue with thought leaders in the field to disseminate the latest scientific and regulatory developments and facilitate collaboration. The conference features a panel format, with each presenter speaking for 30 minutes followed by Q & A. Our goal is to maximize the efficiency of analgesic drug development.
Register Now (you can register for the full APS Summit or select “Pre-Con Only”). Registration is $150, and includes lunch and refreshments.
You do not need to sign up for the full APS meeting to attend APS-CAT, but APS offers 2 additional days of scientific content.
Contact:
Hadley Rakowski
Lotus Clinical Research
802-343-5470
hrakowski@lotuscr.com
www.lotuscr.com
